Literature DB >> 15701472

Dramatically improved left ventricular function after biventricular pacemaker implantation--a case report.

Alan Bulava1, Jan Lukl, Marcela Skvarilová, Dan Marek.   

Abstract

A case study of a patient suffering from severe chronic congestive heart failure resulting from ischemic cardiomyopathy in whom a biventricular (BiV) pacing system was implanted is reported. After a 1-year follow-up, left ventricular (LV) ejection fraction improved dramatically from an initial 15% to 60%, left ventricular end-diastolic diameter decreased, as did left atrial dimension. Tissue Doppler data and acute hemodynamic measurements taken during the biventricular pacemaker implantation procedure are presented. The case represents an exceptional example of left ventricular reverse remodeling with practically normalized left ventricular function after 1 year of synchronized pacing.

Entities:  

Mesh:

Year:  2005        PMID: 15701472     DOI: 10.1016/j.ejheart.2004.09.017

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  3 in total

1.  Is "hyper response" to cardiac resynchronization therapy in patients with nonischemic cardiomyopathy a recovery, a remission, or a control?

Authors:  Philippe Castellant; Erwann Orhan; Valerie Bertault-Valls; Marjaneh Fatemi; Yves Etienne; Jean-Jacques Blanc
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-10       Impact factor: 1.468

2.  Contractile reserve assessed by dobutamine test identifies super-responders to cardiac resynchronization therapy.

Authors:  Dejan Vukajlovic; Goran Milasinovic; Lazar Angelkov; Velibor Ristic; Milosav Tomovic; Ruzica Jurcevic; Petar Otasevic
Journal:  Arch Med Sci       Date:  2014-08-29       Impact factor: 3.318

3.  Echocardiographic markers of dyssynchrony as predictors of super-response to cardiac resynchronisation therapy - a pilot study.

Authors:  V A Kuznetsov; A M Soldatova; J D Kasprzak; D V Krinochkin; N N Melnikov
Journal:  Cardiovasc Ultrasound       Date:  2018-10-02       Impact factor: 2.062

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.